Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

  • Marc A. Pfeffer
    Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
  • Brian Claggett
    Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
  • Eldrin F. Lewis
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Palo Alto, CA (E.F.L.).
  • Christopher B. Granger
    Duke University Medical Center, Durham, NC (C.B.G.).
  • Lars Køber
    Rigshospitalet, Blegdamsvej, University of Copenhagen, Denmark (L.K.).
  • Aldo P. Maggioni
    ANMCO Research Center, Florence, Italy (A.P.M.).
  • Douglas L. Mann
    Washington University School of Medicine, St. Louis, MO (D.L.M.).
  • John J.V. McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Scotland (J.J.V.M., M.C.P.).
  • Jean-Lucien Rouleau
    Montréal Heart Institute, University of Montréal, Quebec, Canada (J.-L.R.).
  • Scott D. Solomon
    Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
  • Philippe Gabriel Steg
    Université de Paris, AP-HP (Assistance Publique-Hôpitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148, France (P.G.S.).
  • Otavio Berwanger
    Academic Research Organization – Hospital Israelita Albert Einstein, São Paulo-SP, Brazil (O.B.).
  • Maja Cikes
    Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Croatia (M.C.).
  • Carmine G. De Pasquale
    Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, Australia (C.G.D.P.).
  • Alberto Fernandez
    Cardiology Service, Sanatorio Modelo Quilmes, Argentina (A.F.).
  • Gerasimos Filippatos
    HF Unit at the Attikon University Hospital, Athens, Greece (G.F.).
  • Karola Jering
    Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
  • Ulf Landmesser
    Department of Cardiology, Charité University Medicine Berlin, German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin Institute of Health, Germany (U.L.).
  • Venugopal Menon
    Cardiovascular Medicine, Cleveland Clinic, OH (V.M.).
  • Béla Merkely
    Semmelweis University, Heart and Vascular Center, Budapest, Hungary (B.M.).
  • Mark C. Petrie
    Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
  • Ivo Petrov
    Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria (I.P.).
  • Morten Schou
    Department of Cardiology, Herlev-Gentofte University Hospital, Copenhagen, Denmark (M. Schou).
  • Michele Senni
    Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy (M. Senni).
  • David Sim
    National Heart Centre Singapore (D.S.).
  • Peter van der Meer
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (P.v.d.M.).
  • Martin Lefkowitz
    Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L., Y.Z., Y.W.).
  • Yinong Zhou
    Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L., Y.Z., Y.W.).
  • Yi Wang
    Novartis Pharmaceutical Corporation, East Hanover, NJ (M.L., Y.Z., Y.W.).
  • Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA (E.B.).

収録刊行物

  • Circulation

    Circulation 145 (1), 87-89, 2022-01-04

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ